Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 31;43(1):BSR20222102.
doi: 10.1042/BSR20222102.

Dual inhibition of HSF1 and DYRK2 impedes cancer progression

Vasudha Tandon #  1 , Rita Moreno #  1 , Kira Allmeroth  2 , Jean Quinn  3 , Sandra E Wiley  4 , Lynden G Nicely  1 , Martin S Denzel  2   5 , Joanne Edwards  3 , Laureano de la Vega  1 , Sourav Banerjee  1
Affiliations
Free article

Dual inhibition of HSF1 and DYRK2 impedes cancer progression

Vasudha Tandon et al. Biosci Rep. .
Free article

Abstract

Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a tractable strategy to target cancers sensitive to proteotoxic stress; however, the development of HSF1 inhibitors remains in its infancy. Importantly, multiple other kinases have been shown to redundantly activate HSF1 that promoted ideas to directly target HSF1. The eventual development of direct HSF1 inhibitor KRIBB11 suggests that the transcription factor is indeed a druggable target. The current study establishes that concurrent targeting of HSF1 and DYRK2 can indeed impede cancer by inducing apoptosis faster than individual targetting. Furthermore, targeting the DYRK2-HSF1 axis induces death in proteasome inhibitor-resistant cells and reduces triple-negative breast cancer (TNBC) burden in ectopic and orthotopic xenograft models. Together the data indicate that cotargeting of kinase DYRK2 and its substrate HSF1 could prove to be a beneficial strategy in perturbing neoplastic malignancies.

Keywords: inhibition; myeloma; proteasomes; stress kinases.

Similar articles

See all similar articles

Publication types

Substances

LinkOut - more resources